Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619001494123p
Ethics application status
Submitted, not yet approved
Date submitted
16/10/2019
Date registered
29/10/2019
Date last updated
12/02/2020
Date data sharing statement initially provided
29/10/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
The comparison of a NanoCelle™ cannabis formulation (NanaBis™) and a cannabis oil formulation derived from the same raw cannabis oil material administered in equal concentration to the oral mucosa in healthy volunteers: a pharmacokinetic, open-label, randomised exploratory study.
Query!
Scientific title
The comparison of a NanoCelle™ cannabis formulation (NanaBis™) and a cannabis oil formulation derived from the same raw cannabis oil material administered in equal concentration to the oral mucosa in healthy volunteers: a pharmacokinetic, open-label, randomised exploratory study.
Query!
Secondary ID [1]
299568
0
Nill known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pain
314841
0
Query!
Condition category
Condition code
Alternative and Complementary Medicine
313179
313179
0
0
Query!
Other alternative and complementary medicine
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Sampling Method: Randomisation
Allocation: NanaBis™ (cannabis spray) group or cannabis oil group
Intervention Model: Comparison study
Masking: Open label
This is an open label, randomised comparison study. This study will be performed in healthy subjects to determine the absorption and bioavailability properties of a micellised (NanoCelle™) THC:CBD formulation in the form of an oro-buccal spray (NanaBis™) (treatment 1) when compared to an equal concentration cannabis oil formulation derived from the same raw cannabis oil material (treatment 2). NanaBis™ contains 7.5 mg THC and 7.5 mg CBD in 0.9 mL in 6 sprays. The cannabis oil formulation contains 7.5 mg THC and 7.5 mg CBD in 0.9 mL.
Subjects will be screened from 28 days up to 2 days prior to study day 1 (dosing day). Enrolled participants will be admitted into the study facility on the evening of study day 0 and will be advised to fast from midnight. Randomisation to treatment 1 or treatment 2 will occur at this time. On study day 1 (morning), a pre-dose blood sample will be collected from the participants while fasting. Subsequently, 6 sprays of NanaBis™ (treatment 1) will be administered to the buccal mucosa of 5 volunteers and 0.9 mL drops of a cannabis oil formulation (treatment 2) will be administered sublingually to the remaining 5 volunteers at 0 minutes. Additional blood samples will be collected at the following time points: 30, 60, 90, 120, 180, 240, 360 minutes, 12 hours and at 24 hours. On study Day 2, after the 24 hours blood sample has been collected, participants will be discharged from the study facility.
Participants will be closely monitored for adverse events while participating in the study. All blood samples will be processed at the study facility and plasma aliquots will be extracted from the whole blood samples and frozen at -80 degrees celsius. Plasma samples will be shipped to the analysing Laboratory in Thebarton SA (Agilex Biolabs).
Query!
Intervention code [1]
315824
0
Treatment: Drugs
Query!
Comparator / control treatment
Cannabis oil formulation
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
321696
0
Composite primary outcome: Pharmacokinetic properties of the two formulations as measured by plasma assay of THC, CBD and THC/CBD metabolites pharmacokinetics (AUC and T1/2)
Query!
Assessment method [1]
321696
0
Query!
Timepoint [1]
321696
0
Blood sample collection for plasma analysis of THC, CBD and metabolites on study day 1 &2 at the following time points:
Baseline:30, 60, 90, 120, 180, 240, 360 minutes, 12 hours and at 24 hours post administration of treatment 1 or 2 (NanaBis or Cannabis oil formulation).
Query!
Secondary outcome [1]
376318
0
No secondary outcome
Query!
Assessment method [1]
376318
0
Query!
Timepoint [1]
376318
0
No secondary outcome
Query!
Eligibility
Key inclusion criteria
1) Participants greater than or equal to 18 years of age at time of entry on the study;
2) Participants have the cognitive ability to understand the informed consent process and to give and sign informed consent to the experimental treatment;
3) Participants agree to undergo the insertion of an intravenous cannula on study day 1 for approximately 24 hours with multiple blood draws;
4) Participants agree to adhere to the study protocol;
5) Participants agree to abstain from using any other products containing cannabinoids for the duration of their participation in the study (from the signing of the informed consent to study completion on study day 7);
6) Participants are willing to take the study medication, which may exhibit psychoactive effects;
7) Participants consent to having urine tests for pregnancy if applicable;
8) Participants consent to having urine tests for recent illicit substance use including THC;
9) Participants have no history of any chronic diseases;
10) 10) Participants agree to not drive and/or operate heavy machinery from study day 0 to study day 7 (6 days after administration of the IP on study day 1).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Key Exclusion Criteria:
1) Any clinically relevant abnormal findings which, in the opinion of the investigators / clinicians, may put the participant at risk of adverse events because of participation in the clinical trial including: physical examination, clinical chemistry, haematology, urinalysis, vital signs;
2) Current or previous allergies or allergic responses to herbal medicines of any kind;
3) Active substance abuse (alcohol or drug dependency);
4) Subjects who test positive to illicit substance use including THC during the screening visit assessments and on study day 0;
5) Pregnant or nursing an infant;
6) Any psychiatric disorders by history or examination that would prevent completion of the study or result in possible adverse events for the participant;
7) Elevated liver enzymes 2x normal limits;
8) The current use of any dietary and herbal supplements (15 days wash-out period required);
9) The current use of any over-the-counter or prescription medications (15 days wash-out period required).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Phase 0
Query!
Type of endpoint/s
Pharmacokinetics
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
15/06/2020
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Funding & Sponsors
Funding source category [1]
304052
0
Commercial sector/Industry
Query!
Name [1]
304052
0
Medlab Clinical
Query!
Address [1]
304052
0
66 Mc Cauley st, Alexandria, Nsw, 2015.
Query!
Country [1]
304052
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Medlab Clinical
Query!
Address
66 Mc Cauley st, Alexandria, Nsw, 2015.
Query!
Country
Australia
Query!
Secondary sponsor category [1]
304246
0
None
Query!
Name [1]
304246
0
Query!
Address [1]
304246
0
Query!
Country [1]
304246
0
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
304544
0
National Institute of Integrative Medicine (EC0046)
Query!
Ethics committee address [1]
304544
0
21 Burwood Rd, Hawthorn VIC 3122
Query!
Ethics committee country [1]
304544
0
Australia
Query!
Date submitted for ethics approval [1]
304544
0
11/10/2019
Query!
Approval date [1]
304544
0
Query!
Ethics approval number [1]
304544
0
Query!
Summary
Brief summary
For this study, Medlab Clinical proposes to conduct an open label, randomised comparison study to investigate the absorption and bioavailability characteristics of its NanoCelle™ nanotechnology cannabis formulation compared to a cannabis oil formulation at the same concentration, derived from the same raw cannabis oil material (same raw material batch) in order to progress its research into the NanoCelleTM delivery platform with respect to a cannabis extract.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
97330
0
Dr James Kuo
Query!
Address
97330
0
Scientia Clinical Research, 5 Bright Building Corner High, Avoca St, Randwick NSW 2031
Query!
Country
97330
0
Australia
Query!
Phone
97330
0
+6102 9382 5800
Query!
Fax
97330
0
Query!
Email
97330
0
[email protected]
Query!
Contact person for public queries
Name
97331
0
Miss Kavya Potlapelly
Query!
Address
97331
0
Medlab Clinical Ltd, 66 Mc Cauley st, Alexandria, NSW, 2015.
Query!
Country
97331
0
Australia
Query!
Phone
97331
0
+61 0281880311
Query!
Fax
97331
0
Query!
Email
97331
0
[email protected]
Query!
Contact person for scientific queries
Name
97332
0
Prof Luis Vitetta
Query!
Address
97332
0
Medlab Clinical Ltd, Mc Cauley st, Alexandria, NSW, 2015.
Query!
Country
97332
0
Australia
Query!
Phone
97332
0
+61 280941939
Query!
Fax
97332
0
Query!
Email
97332
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
No comments
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF